United States patent law

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

Friday, March 27, 2020 - 12:30am

IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.

Key Points: 
  • IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.
  • A public copy of the patent is available on the USPTO website.
  • A patent for an invention is the grant of a property right to the inventor, issued by the USPTO.
  • The company is based in Maryland, U.S.A. Our website: www.igcinc.us .Twitter @IGCIR
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005803/en/

Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus

Thursday, March 26, 2020 - 12:00pm

The purpose of a Markman Hearing is to determine the precise meaning of words from patent claims that are in dispute in a patent infringement lawsuit.

Key Points: 
  • The purpose of a Markman Hearing is to determine the precise meaning of words from patent claims that are in dispute in a patent infringement lawsuit.
  • No ultimate determination of infringement or validity of the patents has been determined at this point.
  • The Markman Hearing Order, issued by the United States District Court of Delaware, has been posted on Lipocine's website at: https://ir.lipocine.com/presentations .
  • Lipocine has a pending suit against Clarus in the United States District Court of Delaware alleging that Clarus's JATENZO product infringes Lipocine's U.S. patents: 9,034,858; 9,205,057; 9,480,690; and 9,757,390.

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Thursday, March 19, 2020 - 1:00pm

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP molecule.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP molecule.
  • Based on these results the company has filed for patent protection with the United States Patent and Trademark Office (USPTO) for the application of DED.
  • Dry Eye Disease is one of the most common ocular problems with an estimated prevalence of almost 5-million people over the age of fifty in the United States alone.
  • Current therapies for dry eye are palliative with a focus on the replacement of tears to reduce symptoms.

US Patent Practice | London, United Kingdom - June 11-12, 2020 - ResearchAndMarkets.com

Tuesday, March 17, 2020 - 12:11pm

The "US Patent Practice" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Patent Practice" conference has been added to ResearchAndMarkets.com's offering.
  • This highly interactive seminar will give you a comprehensive understanding of the US patent system and enable you to work more effectively with your US counterparts.
  • It will highlight the important differences between US and European patent practice and provide you with the opportunity for in-depth discussions about prosecution practice and procedure throughout the two days.
  • Offering a wide-ranging and detailed understanding, this seminar covers what every European patent practitioner should know about US patent practice.

Aesthetics Biomedical Announces Issuance of U.S. Patent For Biologic Preserving Composition and Methods of Use

Wednesday, March 11, 2020 - 4:00pm

PHOENIX, March 11, 2020 /PRNewswire-PRWeb/ --Aesthetics Biomedical Inc, a company committed to the development and distribution of innovative aesthetic devices, products, and services for the global market, announces issuance of U.S. Patent for Biologic Preserving Composition and Methods of Use.

Key Points: 
  • PHOENIX, March 11, 2020 /PRNewswire-PRWeb/ --Aesthetics Biomedical Inc, a company committed to the development and distribution of innovative aesthetic devices, products, and services for the global market, announces issuance of U.S. Patent for Biologic Preserving Composition and Methods of Use.
  • The United States Patent and Trademark Office has issued Aesthetics Biomedical the U.S. Patent No.
  • The issuance of this patent comes just months after the company launched the proprietary SoME Skincare product.
  • This patent, further positions Aesthetics Biomedical's SoME Skincare brand at the forefront of innovation in the physician dispensed topical-use skincare product category.

Fish & Richardson Named Most Active Law Firm at Patent Trial and Appeal Board for Fourth Consecutive Year

Monday, March 9, 2020 - 5:26pm

BOSTON, March 9, 2020 /PRNewswire/ -- Fish & Richardson has been named the most active law firm at the Patent Trial and Appeal Board (PTAB) for the fourth consecutive year according to a recent Lex Machina report that analyzedinter partes (IPR) reviews challenges filed in 2019.

Key Points: 
  • BOSTON, March 9, 2020 /PRNewswire/ -- Fish & Richardson has been named the most active law firm at the Patent Trial and Appeal Board (PTAB) for the fourth consecutive year according to a recent Lex Machina report that analyzedinter partes (IPR) reviews challenges filed in 2019.
  • Fish had more appearances than any other firm appearing in a total of 116 IPRs in 2019.
  • Since the inception of post-grant proceedings in 2012, Fish has appeared in 1,138 proceedings, far exceeding its closest competitor at the PTAB.
  • Fish & Richardson, the premier global intellectual property law firm, is trusted by the world's most innovative and influential companies.

ClearOne Prevails Again – Wins Against Shure Regarding the Validity of ClearOne’s BMA Patent

Monday, March 9, 2020 - 1:10pm

Shure challenged the validity of the 553 Patent through the inter partes review process in the PTO after ClearOne accused Shure of infringing multiple ClearOne patents covering fundamental BMA technology.

Key Points: 
  • Shure challenged the validity of the 553 Patent through the inter partes review process in the PTO after ClearOne accused Shure of infringing multiple ClearOne patents covering fundamental BMA technology.
  • After a one-year in-depth trial, the PTAB rejected Shures arguments and agreed with ClearOne that the 553 Patent was valid.
  • Last year ClearOne obtained a preliminary injunction against Shure after demonstrating that Shure was likely infringing a different ClearOne patent, and the Federal Circuits decision puts ClearOne in an even better position as we prepare for trial.
  • ClearOne has asserted that Shure infringes the 553 Patent as well as U.S. Patent No.

US Patent Practice - 2 Day Seminar (London, United Kingdom - December 3-4, 2020) - ResearchAndMarkets.com

Thursday, March 5, 2020 - 3:48pm

Are you up to date with the latest court decisions and best practice?

Key Points: 
  • Are you up to date with the latest court decisions and best practice?
  • This highly interactive seminar will give you a comprehensive understanding of the US patent system and enable you to work more effectively with your US counterparts.
  • It will highlight the important differences between US and European patent practice and provide you with the opportunity for in-depth discussions about prosecution practice and procedure throughout the two days.
  • Offering a wide-ranging and detailed understanding, this seminar covers what every European patent practitioner should know about US patent practice.

RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.

Wednesday, March 4, 2020 - 2:00pm

The Option Agreement identifies United States Patents 9,006,233, 9,597,342, and 10,259,815 and Canadian patent application serial No.

Key Points: 
  • The Option Agreement identifies United States Patents 9,006,233, 9,597,342, and 10,259,815 and Canadian patent application serial No.
  • For a more complete description of the Option Agreement, refer to the complete Form 8-K filing and its Exhibits.
  • Prior to the expiration of the Option Agreement, the parties intend to enter into a Patent License Agreement substantially in the form of Appendix I to the Option Agreement.
  • The Form of Patent License calls for the Company to be able to practice the licensed subject matter.

Worksport Achieves First Canadian Patent Claim Allowance

Wednesday, March 4, 2020 - 1:00pm

Worksport Ltd has be awarded patent claims in Canada, marking the companies first ever Canadian patent asset.

Key Points: 
  • Worksport Ltd has be awarded patent claims in Canada, marking the companies first ever Canadian patent asset.
  • This marks Worksports first Canadian patent asset and another milestone for the company and its shareholders alike.
  • Worksport is now enviably positioned in both the U.S and Canadian markets to begin releasing its unique truck bed cover systems said Steven Rossi, CEO of Worksport.
  • This follows the USPTO (U.S Patent and Trademark Office) allowing all claims for the same patent application in November, 2019.